Fertility Regulator Updates & Insights

UK Fertility Regulator Calls for Modernization of Laws Amidst Rapid Technological Advances

The United Kingdom’s Human Fertilisation and Embryology Authority (HFEA) is urging substantial reform of its governing legislation as reproductive technologies evolve at an unprecedented pace. Julia Chain, chair of the HFEA, outlined key areas of concern and progress during a recent keynote address, highlighting the complex ethical and regulatory challenges facing the field.

Chain’s remarks centered on a range of topics, from expanded carrier screening to the controversial practice of preimplantation genetic testing for polygenic traits (PGT-P). She emphasized the need for updated guidelines to navigate these advancements responsibly.

Expanded Carrier Screening: Proceed with Caution

The HFEA is currently developing national guidelines for expanded carrier screening (ECS), a process that screens prospective parents for a wider range of genetic conditions than traditional carrier testing. Chain questioned whether wider implementation should occur simply because the technology allows it, noting that guidelines are expected soon.

PGT-A Remains a Point of Contention

Preimplantation genetic testing for aneuploidy (PGT-A), often considered a fertility treatment “add-on,” continues to spark debate. The HFEA classifies PGT-A using a “traffic light” system – red for potential safety concerns, green for effectiveness, and grey for insufficient evidence – depending on its application. Chain acknowledged the lively discussion surrounding PGT-A and indicated it will remain a controversial topic.

Successes and New Complexities in PGT-M and PGT-SR

In contrast to PGT-A, PGT-M (for monogenic diseases) and PGT-SR (for structural rearrangements) have been lauded as “a real success story for UK fertility treatment.” The number of inherited conditions for which testing is licensed has significantly expanded. However, the move towards whole genome sequencing introduces new complexities, prompting the HFEA to promise updated guidance in 2026.

PGT-P: Illegal in the UK, But a Growing Concern

Chain reiterated that PGT-P, testing embryos for predisposition to certain traits, remains illegal in the UK and cannot be offered by licensed clinics. A significant challenge arises from patients obtaining genomic data from UK clinics and seeking PGT-P services in other jurisdictions, particularly the United States, then requesting embryo transfers based on those results. The HFEA has firmly stated that UK clinicians should not utilize PGT-P results in embryo selection, but the question of patient autonomy remains.

Mitochondrial Donation: Progress and Limitations

Significant progress has been made in mitochondrial donation, with eight healthy babies born in the UK with donated mitochondria. This milestone came a decade after the UK became the first country to legislate permitting the procedure to prevent the transmission of mitochondrial disease. However, the use of mitochondrial donation as a treatment for infertility is not currently permitted, remaining limited to cases of high risk of transmitting serious mitochondrial disease.

Gamete Donation and the Erosion of Anonymity

The rise of direct-to-consumer genetic testing is fundamentally altering the landscape of gamete donation. According to Chain, this technology has “driven a coach and horses through our notions of anonymity and undermines the integrity of the current legislative framework.” The HFEA advocates for granting families access to donor identity information from the child’s birth.

Calls for Legislative Reform

Chain underscored that the current Human Fertilisation and Embryology Act is outdated and unable to keep pace with modern developments. The HFEA has recommended substantial reforms to the government, a sentiment that resonated with many in attendance at the conference.

The HFEA’s call for modernization reflects a broader need for ongoing dialogue and adaptation within the rapidly evolving field of assisted reproductive technology.